Evaluation of the carcinogenicity of inorganic arsenic

Critical Reviews in Toxicology

Volumn 43, Issue 9, 2013, Pages 711-752

  Cohen, Samuel M ^a,b   Arnold, Lora L ^a   Beck, Barbara D ^c   Lewis, Ari S ^c   Eldan, Michal ^d,e  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c GRADIENT   (United States)

^d Organic Arsenical Products Task Force   (United States)

^e Luxembourg Industries   (Israel)

Author keywords

Arsenic; Bladder; Cell proliferation; Cytotoxicity; Epidemiology; Lung; Skin

Indexed keywords

ARSENIC; CARCINOGEN; DNA; DRINKING WATER; ORGANOARSENIC DERIVATIVE; THIOL GROUP;

BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CARCINOGENESIS; CARCINOGENICITY; CELL INTERACTION; CELL MEMBRANE TRANSPORT; CELL PROLIFERATION; CELL TYPE; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; GENOTOXICITY; GOVERNMENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LUNG CANCER; MITOSIS SPINDLE; NONHUMAN; PROTEIN FUNCTION; REVIEW; SKIN CANCER; TOXICOKINETICS; UNITED STATES; UROTHELIUM;

ANIMALS; ARSENIC; CARCINOGENS; CELL PROLIFERATION; DRINKING WATER; ENVIRONMENTAL EXPOSURE; HUMANS; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84884650215     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2013.827152     Document Type: Review

References (338)

1. Adeyemi A, Garelick H, Priest ND. (2000). A biokinetic model to describe the distribution and excretion of arsenic by man following acute and chronic intakes of arsenite/arsenate compounds by ingestion. Hum Exp Toxicol, 29, 891-902
2. Agency for Toxic Substances and Disease Registry (ATSDR). (2007). Toxicological Profile for Arsenic (Final). Available at: http://www.atsdr.cdc. gov/toxprofiles/tp2.pdf. [last accessed 11 Feb 2013]
3. Agency for Toxic Substances and Disease Registry (ATSDR). (2012a). Biomonitoring Summary. Arsenic. Available at: http://www.cdc.gov/biomonitoring/ Arsenic-BiomonitoringSummary.html. [last accessed 12 Apr 2013]
4. Agency for Toxic Substances and Disease Registry (ATSDR). (2012b). Toxic Substances Portal - Arsenic Available at: http://www.atsdr.cdc.gov/toxfaqs/tf. asp?id=19&tid=3. [last accessed 12 Apr 2013]
5. Agency for Toxic Substances and Disease Registry (ATSDR). (2012c). Draft Toxicological Profile for Chromium (Final). Available at: http://www.atsdr.cdc. gov/toxprofiles/tp7.pdf. [last accessed 13 Dec 2012]
6. Ahlborn GJ, Nelson GM, Grindstaff RD, et al. (2009). Impact of life stage and duration of exposure on arsenic-induced proliferative lesions and neoplasia in C3H mice. Toxicology, 262, 106-13
7. Ahsan H, Chen Y, Parvez F, et al. (2006). Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: baseline results from the Health Effects of Arsenic Longitudinal Study. Am J Epidemiol, 163, 1138-48
8. Andersen ME, Meek E, Boorman GA, et al. (2000). Lessons learned in applying the U.S. EPAs proposed cancer guidelines to specific compounds. Toxicol Sci, 53, 159-72
9. Andrewes P, Demarini DM, Funasaka K, et al. (2004). Do arsenosugars pose a risk to human health? The comparative toxicities of a trivalent and pentavalent arsenosugar. Environ Sci Technol, 38, 4140-8
10. Aposhian HV. (1997). Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol, 37, 397-419
11. Aposhian HV, Gurzau ES, Le C, et al. (2000). Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem Res Toxicol, 13, 693-7
12. Argos M, Kalra T, Pierce BL, et al. (2011). A prospective study of arsenic exposure from drinking water and incidence of skin lesions in Bangladesh. Am J Epidemiol, 174, 185-94
13. Arnold LL, Cano M, St John M, et al. (1999). Effects of dietary dimethylarsinic acid on the urine and urothelium of rats. Carcinogenesis, 20, 2171-9
14. Arnold LL, Eldan M, van Gemert M, et al. (2003). Chronic studies evaluating the carcinogenicity of monomethylarsonic acid in rats and mice. Toxicology, 190, 197-219
15. Arnold LL, Nyska A, Eldan M, et al. (2006). Dimethylarsinic acid: results of chronic toxicity/oncogenicity studies in F344 rats and B6C3F1 mice. Toxicology, 223, 82-100
16. Arnold LL, Kakiuchi-Kiyota S, Pennington KL, Cohen SM. (2011). Cytotoxicity of arsenicals on human bronchial epithelial cells in vitro. Toxicologist Abstract #2655
17. Arnold LL, Suzuki S, Yokohiro M et al. (2013).) Time course of urothelial changes in rats and mice orally administered arsenite. Toxicol Pathol. doi: 10.1177/0192623313489778
18. Baastrup R, Srensen M, Balstrm T, et al. (2008). Arsenic in drinkingwater and risk for cancer in Denmark. Environ Health Perspect, 116, 231-7
19. Bae DS, Gennings C, Carter Jr WH, et al. (2001). Toxicological interactions among arsenic, cadmium, chromium, and lead in human keratinocytes. Toxicol Sci, 63, 132-42
20. Bartel M, Ebert F, Leffers L, et al. (2011). Toxicological characterization of the inorganic and organic arsenic metabolite thio-DMA in cultured human lung cells. J Toxicol doi: 10.1155/2011/373141
21. Bartolotta SA, Pacskowski MG, Hick A, Carballo MA. (2011). Micronuclei assay in exfoliated buccal cells from individuals exposed to arsenic in Argentina. Arch Environ Contam Toxicol, 61, 337-43
22. Basu A, Ghosh P, Das JK, et al. (2004). Micronuclei as biomarkers of carcinogen exposure in populations exposed to arsenic through drinking water in West Bengal, India: a comparative study in three cell types. Cancer Epidemiol Biomark Prev, 13, 820-7
23. Bates MN, Smith AH, Cantor KP. (1995). Case-control study of bladder cancer and arsenic in drinking water. Am J Epidemiol, 141, 523-30
24. Bates MN, Rey OA, Biggs ML, et al. (2004). Case-control study of bladder cancer and exposure to arsenic in Argentina. Am J Epidemiol, 159, 381-9
25. Beane Freeman LE, Dennis LK, Lynch CF, et al. (2004). Toenail arsenic content and cutaneous melanoma in Iowa. Am J Epidemiol, 160, 679-87
26. Begum M, Horowitz J, Hossain MI. (2012). Low-dose risk assessment for arsenic: a meta-analysis approach. Asia Pac J Public Health doi:10.1177/ 1010539512466568
27. Bencko V, Rames J, Fabianova E, et al. (2009). Ecological and human health risk aspects of burning arsenic-rich coal. Environ Geochem Health, 31, 239-43
28. Berenblum I, Shubik P. (1947). A new, quantitative, approach to the study of the stages of chemical carcinogenesis in the mouses skin. Br J Cancer, 1, 383-91
29. Boellmann F, Zhang L, Clewell HJ, et al. (2010). Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. Toxicol Sci, 117, 404-17
30. Bomhard EM, Gelbke H-P, Schenk H, et al. (2013) Evaluation of the carcinogenicity of gallium arsenide. Crit Rev Toxicol, 43, 436-66
31. Boobis AR, Cohen SM, Dellarco V, et al. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol, 36, 781-92
32. Boobis AR, Doe JE, Heinrich-Hirsch B, et al. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol, 38, 87-96
33. Boorman GA, Eustis SL. (1990). Lung. In: Boorman GA, Eustic SL, Elwell MR, Montgomery CA Jr eds. Pathology of the Fischer Rat. Reference and Atlas. San Diego: Academic Press Inc., 350-7
34. Borak J, Hosgood HD. (2007). Seafood arsenic: implications for human risk assessment. Regul Toxicol Pharmacol, 47, 204-12
35. Boutwell RK. (1964). Some biological aspects of skin carcinogenesis. Prog Exp Tumor Res, 4, 207-50
36. Brown KG. (2007). How creditable are cancer risk estimates from the S.W. Taiwan database for arsenic in drinking water? Hum Ecol Risk Assess, 13, 180-90
37. Brown AC, Bullock CG, Gilmore RS, et al. (1985). Mitochondrial granules: are they reliable markers for heavy metal cations? J Anat, 140, 659-67
38. Calatayud M, Gimeno J, Velez D, et al. (2010). Characterization of the intestinal absorption of arsenate, monomethylarsonic acid, and dimethylarsinic acid using the Caco-2 cell line. Chem Res Toxicol, 23, 547-56
39. Calatayud M, Barrios JA, Velez D, Devesa V. (2012). In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol, 25, 446-53
40. Cano M, Arnold LL, Cohen SM. (2001). Evaluation of diet and dimethylarsinic acid on the urothelium of Syrian golden hamsters. Toxicol Pathol, 29, 600-6
41. Carbrey JM, Song L, Zhou Y, et al. (2009). Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice. Proc Natl Acad Sci. USA, 106, 15956-60
42. Celik I, Gallicchio L, Boyd K, et al. (2008). Arsenic in drinking water and lung cancer: a systematic review. Environ Res, 108, 48-55
43. Centers for Disease Control and Prevention. (2009, revised 2012). The Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, September, 2012. US Department of Health and Human Services. Available at: http://www.cdc.gov/exposurereport/pdf/FourthReport-UpdatedTables-Sep2012.pdf 314p. [last accessed 28 Sept 2012]
44. Challenger F. (1951). Biological methylation. Adv Enzymol Relat Subj Biochem, 12, 429-91
45. Chavan H, Oruganti M, Krishnamurthy P. (2011). The ATP-binding cassette transporter ABCB6 is induced by arsenic and protects against arsenic cytotoxicity. Toxicol Sci, 120, 519-28
46. Chen B, Arnold LL, Cohen SM, et al. (2011). Mouse arsenic (3 oxidation state) methyltransferase genotype affects metabolism and tissue dosimetry of arsenicals after arsenite administration in drinking water. Toxicol Sci, 124, 320-6
47. Chen B, Lu X, Shen S, et al. (2013). Arsenic speciation in the blood of arsenite-treated F344 rats. Chem Res Toxicol, 26, 952-62
48. Chen CJ, Wang CJ. (1990). Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res, 50, 5470-5
49. Chen CJ, Chuang YC, Lin TM, Wu HY. (1985). Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res, 45, 5895-9
50. Chen CJ, Chuang YC, You SL, et al. (1986). A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer, 53, 399-405
51. Chen CJ, Wu MM, Lee SS, et al. (1988a) Atherogenicity and carcinogenicity of high-arsenic artesian well water. Arteriosclerosis, 8, 452-60
52. Chen CJ, Kuo TL, Wu MM. (1988b). Arsenic and cancers. Lancet, 1, 414-15
53. Chen YC, Guo YL, Su HJ, et al. (2003a). Arsenic methylation and skin cancer risk in Southwestern Taiwan. J. Occup Environ Med, 45, 241-8
54. Chen YC, Su HJ, Guo YL, et al. (2003b). Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control, 14, 303-10
55. Chen C, Hsu L, Chiou H, et al. (2004a). Ingested arsenic, cigarette smoking, and lung cancer risk. J Am Med Assoc, 292, 2984-90
56. Chen H, Li SF, Liu J, et al. (2004b). Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis., 25, 1779-86
57. Chen PH, Lan CC, Chiou MH, et al. (2005). Effects of arsenic and UVB on normal human cultured keratinocytes: impact on apoptosis and implication on photocarcinogenesis. Chem Res Toxicol, 18, 139-44
58. Chen Y, Graziano JH, Parvez F, et al. (2006). Modification of risk of arsenic-induced skin lesions by sunlight exposure, smoking, and occupational exposures in Bangladesh. Epidemiology, 17, 459-67
59. Chen Y, OBrien T, Del Razo LM, et al. (2008). Tissue levels of arsenicals and skin tumor response following administration of monomethylarsonous acid and arsenite to K6/ODC mice. J Environ Pathol Toxicol Oncol., 27, 43-52
60. Chen Y, Parvez F, Gamble M, et al. (2009). Arsenic exposure at low-tomoderate levels and skin lesions, arsenic metabolism, neurological functions, and biomarkers for respiratory and cardiovascular diseases: review of recent findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh. Toxicol Appl Pharmacol, 239, 184-92
61. Chen CL, Chiou HY, Hsu LI, et al. (2010a). Arsenic in drinking water and risk of urinary tract cancer: a follow-up study from northeastern Taiwan. Cancer Epidemiol Biomarkers Prev, 19, 101-10
62. Chen CL, Chiou HY, Hsu LI, et al. (2010b). Ingested arsenic, characteristics of well water consumption and risk of different histological types of lung cancer in northeastern Taiwan. Environ Res, 110, 455-62
63. Chen SJ, Zhou GB, Zhang XW, et al. (2011). From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 117, 6425-37
64. Chilakapati J, Wallace K, Ren H, et al. (2010). Genome-wide analysis of BEAS-2B cells exposed to trivalent arsenicals and dimethylthioarsinic acid. Toxicology, 268, 31-9
65. Chiou HY, Chiou ST, Hsu YH, et al. (2001). Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8102 residents in an arseniasis-endemic area in Northeastern Taiwan. Am J Epidemiol, 153, 411-18
66. Chiou HY, Hsueh YM, Liaw KF, et al. (1995). Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res, 55, 1296-300
67. Chu F, Ren X, Chasse A, et al. (2010). Quantitative mass spectrometry reveals the epigenome as a target of arsenic. Chem Biol Interact, 192, 113-17
68. Clancy HA, Sun H, Passantino L, et al. (2012). Gene expression changes in human lung cells exposed to arsenic, chromium, nickel or vanadium indicate the first steps in cancer. Metallomics, 4, 784-93
69. Clewell HJ, Thomas RS, Gentry PR, et al. (2007). Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report. Toxicol Appl Pharmacol, 222, 388-98
70. Clewell HJ, Thomas RS, Kenyon EM, et al. (2011). Concentration- and time-dependent genomic changes in the mouse urinary bladder following exposure to arsenate in drinking water for up to 12 weeks. Toxicol Sci, 123, 421-32
71. Cohen SM. (1998). Urinary bladder carcinogenesis. Toxicol Pathol, 26, 121-7
72. Cohen SM. (1999). Calcium phosphate-containing urinary precipitate in rat urinary bladder carcinogenesis. IARC Scientific Publications, 147, 175-89
73. Cohen SM. (2004). Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol Sci, 80, 225-9
74. Cohen SM. (2010). Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two year bioassay is no longer necessary. Toxicol Pathol, 38, 487-501
75. Cohen SM, Arnold LL. (2011). Chemical carcinogenesis. Toxicol Sci, 120, 76-92
76. Cohen SM, Ellwein LB. (1990). Cell proliferation in carcinogenesis. Science, 249, 1007-11
77. Cohen SM, Ellwein LB. (1991). Genetic errors, cell proliferation, and carcinogenesis. Cancer Res, 51, 6493-505
78. Cohen SM, Purtilo DT, Ellwein LB. (1991). Pivotal role of increased cell proliferation in human carcinogenesis. Modern Pathol, 4, 371-82
79. Cohen SM, Shirai T, Steineck G. (2000). Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol, 34, 105-15
80. Cohen SM, Arnold LL, Uzvolgyi E, et al. (2002). Possible role of dimethylarsinous acid in dimethylarsinic acid-induced urothelial toxicity and regeneration in the rat. Chem Res Toxicol, 15, 1150-7
81. Cohen SM, Klaunig J, Meek ME, et al. (2004). Evaluating the human relevance of chemically-induced animal tumors. Toxicol Sci, 78, 181-6
82. Cohen SM, Arnold LL, Eldan M, et al. (2006a). Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit Rev Toxicol, 36, 99-133
83. Cohen SM, Boobis AR, Meek ME, et al. (2006b). 4-Aminobiphenyl and DNA reactivity: case study within the context of the 2006 IPCS human relevance framework for analysis of a cancer mode of action for humans. Crit Rev Toxicol, 36, 803-19
84. Cohen SM, Ohnishi T, Arnold LL, Le XC. (2007). Arsenic-induced bladder cancer in an animal model. Toxicol Appl Pharmacol, 222, 258-63
85. Crump KS. (2005). The effect of random error in exposure measurement upon the shape of the exposure response. Dose Response, 3, 456-64
86. Cruzan G, Bus J, Banton M, et al. (2009). Mouse specific lung tumors from CYP2F2-mediated cytotoxic metabolism: an endpoint/toxic response where data from multiple chemicals converge to support a mode of action. Regul Toxicol Pharmacol, 55, 205-18
87. Cruzan G, Bus J, Hotchkiss J, et al. (2012). CYP2F2-generated metabolites, not styrene oxide, are a key event mediating the mode of action of styrene-induced mouse lung tumors. Regul Toxicol Pharmacol, 62, 214-20
88. Csanaky I, Gregus Z. (2005). Role of glutathione in reduction of arsenate and of g-glutamyltranspeptidase in disposition of arsenite in rats. Toxicology, 207, 91-104
89. Cui X, Kobayashi Y, Hayakawa T, Hirano S. (2004). Arsenic speciation in bile and urine following oral and intravenous exposure to inorganic and organic arsenics in rats. Toxicol Sci, 82, 478-87
90. Cui X, Wakai T, Shirai Y, et al. (2006). Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicol Sci, 91, 372-81
91. Cullen WR. (2008). Is arsenic an aphrodisiac? The sociochemistry of an element. Cambridge, United Kingdom: Royal Society of Chemistry
92. Currier JM, Svoboda M, Matous?ek T, et al. (2011). Direct analysis and stability of methylated trivalent arsenic metabolites in cells and tissues. Metallomics, 3, 1347-54
93. Del Razo LM, Garcia-Vargas GG, Vargas H, et al. (1997). Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Arch Toxicol, 71, 211-17
94. Del Razo LM, Styblo M, Cullen WR, Thomas DJ. (2001). Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol, 174, 282-93
95. Del Razo LM, Garcia-Vargas GG, Valenzuela OL, et al. (2011). Exposure to arsenic in drinking water is associated with increased prevalence of diabetes: a cross-sectional study in the Zimapan and Lagunera regions in Mexico. Environ Health doi: 10.1186/1476- 069X-10-73
96. Demicheli C, Frezard F, Pereira FA, et al. (2011). Interaction of arsenite with a zinc finger CCHC peptide: evidence for formation of an As-Znpeptide mixed complex. J Inorg Biochem, 105, 1753-8
97. Dellarco V. (2008). Use of mode of action in human health risk assessment. Available at: http://www.isrtp.org/endocrine-workshop- 02-08/DELLARCO%20SLIDES.pdf. Accessed on[last accessed 15 April 2013]
98. Dilda PJ, Hogg PJ. (2007). Arsenical-based cancer drugs. Cancer Treat Rev, 33, 542-64
99. Dodmane PR, Arnold LL, Kakiuchi-Kiyota S, et al. (2013a). Cytotoxicity and gene expression changes induced by inorganic and organic trivalent arsenicals in human cells. Toxicology, 312, 18-29
100. Dodmane PR, Arnold LL, Muirhead DM, et al. (2013b). Characterization of intracellular inclusions in the urothelium of mice exposed to inorganic arsenic Submitted
101. Drobna Z, Water SB, Devesa V, et al. (2005). Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (3 oxidation state)-methyltransferase. Toxicol Appl Pharmacol, 207, 147-59
102. Drobna Z, Naranmandura H, Kubachka KM, et al. (2009). Disruption of the arsenic (3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem Res Toxicol, 22, 1713-20
103. Drobna Z, Walton FS, Paul DS, et al. (2010). Metabolism of arsenic in human liver: the role of membrane transporters. Arch Toxicol, 84, 3-16
104. Duker AA, Carranza EJ, Hale M. (2005). Arsenic geochemistry and health. Environ Int, 31, 631-41
105. Ebert F, Weiss A, Bultemeyer M, et al. (2011). Arsenicals affect base excision repair by several mechanisms. Mutat Res, 715, 32-41
106. El-Masri HA, Kenyon EM. (2008). Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites. J Pharmacokinet Pharmacodyn, 35, 31-68
107. Engstrom K, Vahter M, Mlakar SJ, et al. (2011). Polymorphisms in arsenic (III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ Health Perspect, 119, 182-8
108. Escudero-Lourdes D, Medeiros MK, Cardenas-Gonzalez MC, et al. (2010). Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model. Toxicol Appl Pharmacol, 244, 162-73
109. Escudero-Lourdes C, Wu T, Camarillo JM, Gandolfi AJ. (2012). Interleukin-8 (IL-8) over-production and autocrine cell activation are key factors in monomethylarsonous acid [MMA(III)]-induced malignant transformation of urothelial cells. Toxicol Appl Pharmacol, 258, 10-8
110. Farmer JG, Johnson LR. (1990). Assessment of occupational exposure to inorganic arsenic based on urinary concentrations and speciation of arsenic. Br J Ind Med, 47, 342-8
111. Fernandez MI, Lopez JF, Vivaldi B, Coz F. (2012). Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure. J Urol, 17, 856-61
112. Francesconi KA, Tanggaard R, McKenzie CJ, Goessler W. (2002). Arsenic metabolites in human urine after ingestion of an arsenosugar. Clin Chem, 48, 92-101
113. Fricke MW, Zeller M, Sun H, et al. (2005). Chromatographic separation and identification of products from the reaction of dimethylarsinic acid with hydrogen sulfide. Chem Res Toxicol, 18, 1821-9
114. Fukuda S, Terasawa M, Shiomi K. (2011). Phosphatidylarsenocholine, one of the major arsenolipids in marine organisms: synthesis and metabolism in mice. Food Chem Toxicol, 49, 1598-603
115. Fukushima S, Cohen SM, Arai M, et al. (1981). Scanning electron microscopic examination of reversible hyperplasia of the rat urinary bladder. Am J Pathol, 102, 373-80
116. Gamble MV, Hall, MN. (2012) Relationship of creatinine and nutrition with arsenic Metabolism. Environ Health Perspect doi: 10.1289/ehp.1104807
117. Gentry PR, McDonald TB, Sullivan DE, et al. (2010). Analysis of genomic dose-response information on arsenic to inform key events in a mode of action for carcinogenicity. Environ Mol Mutagen, 51, 1-14
118. Germolec DR, Spalding J, Yu HS, et al. (1998). Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol, 153, 1775-85
119. Ghosh P, Basu A, Singh KK, Giri AK. (2008). Evaluation of cell types for assessment of cytogenetic damage in arsenic exposed population. Mol Cancer 7:doi:10.1186/1476-4598-7-45
120. Giard DJ, Aaronson SA, Todaro GJ, et al. (1973). In vitro cultivation of human tumors: establishment of cell lines derived from a series of human tumors. J. Natl. Cancer Inst, 51, 1417-23
121. Gilbert-Diamond D, Cottingham KL, Gruber JF, et al. (2011). Rice consumption contributes to arsenic exposure in US women. Proc Natl Acad Sci USA, 108, 20656-60
122. Gong Z, Lu X, Ma M, et al. (2002). Arsenic speciation analysis. Talanta, 58, 77-96
123. Gonick HC. (2011). Lead-binding proteins: a review. J Toxicol 2011, doi: 10.1155/2011/686050
124. Gonzalez KD, Noltner KA, Buzin CH, et al. (2009). Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol, 27, 1250-6
125. Greenfield RE, Ellwein LB, Cohen SM. (1984). A general probabilistic model of carcinogenesis: analysis of experimental urinary bladder cancer. Carcinogenesis, 5, 437-45
126. Greim H, Hartwig A, Reuter U, et al. (2009). Chemically induced pheochromocytomas in rats: mechanisms and relevance for human risk assessment. Crit Rev Toxicol, 39, 695-718
127. Guo HR. (2004). Arsenic level in drinking water and mortality of lung cancer (Taiwan). Cancer Causes Control, 15, 171-7
128. Guo HR, Yu HS, Hu H, Monson RR. (2001). Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, R.O.C.). Cancer Causes Control, 12, 909-16
129. Habib GM. (2010). Arsenite causes down-regulation of Akt and c-Fos, cell cycle dysfunction and apoptosis in glutathione-deficient cells. J Cell Biochem, 110, 363-71
130. Hansen HR, Raab A, Jaspars M, et al. (2004). Sulfur-containing arsenical mistaken for dimethylarsinous acid [DMA(III)] and identified as a natural metabolite in urine: major implications for studies on arsenic metabolism and toxicity. Chem Res Toxicol, 17, 1086-91
131. Hayakawa T, Kobayashi Y, Cui X, Hirano S. (2005). A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch Toxicol, 79, 183-91
132. Hayashi H, Kanisawa M, Yamanaka, K, et al. (1998). Dimethylarsinic acid, a main metabolite of inorganic arsenics, has tumorigenicity and progression effects in the pulmonary tumors of A/J mice. Cancer Lett, 125, 83-8
133. He XQ, Chen R, Yang P, et al. (2007). Biphasic effect of arsenite on cell proliferation and apoptosis is associated with the activation of JNK and ERK1/2 in human embryo lung fibroblast cells. Toxicol Appl Pharmacol, 220, 18-24
134. Heck JE, Andrew AS, Onega T, et al. (2009). Lung cancer in a U.S. population with low to moderate arsenic exposure. Environ Health Perspect, 117, 1718-23
135. Heinrich-Ramm R, Mindt-Prufert S, Szadkowski D. (2002). Arsenic species excretion after controlled seafood consumption. J Chromatogr B Analyt Technol Biomed Life Sci., 778, 263-73
136. Heitland P, Koster HD. (2008). Fast determination of arsenic species and total arsenic in urine by HPLC-ICP-MS: concentration ranges for unexposed German inhabitants and clinical case studies. J Anal Toxicol, 32, 308-14
137. Herbel MJ, Switzer Blum J, Hoeft SE, et al. (2002). Dissimilatory arsenate reductase activity and arsenate-respiring bacteria in bovine rumen fluid, hamster feces, and the termite hindgut. FEMS Microbiol Ecol, 41, 59-67
138. Hinwood AL, Jolley DJ, Sim MR. (1999). Cancer incidence and high environmental arsenic concentrations in rural populations: results of an ecological study. Int J Environ Health Res, 9, 131-41
139. Holsapple MP, Pitot HC, Cohen SM, et al. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci, 89, 51-6
140. Hopenhayn-Rich C, Biggs ML, Smith AH. (1998). Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol, 27, 561-9
141. Hughes MF, Devesa V, Adair BM, et al. (2008). Tissue dosimetry, metabolism and excretion of pentavalent and trivalent dimethylated arsenic in mice after oral administration. Toxicol Appl Pharmacol, 227, 26-35
142. Hughes MF, Edwards BC, Herbin-Davis KM, et al. (2010). Arsenic (3 oxidation state) methyltransferase genotype affects steady-state distribution and clearance of arsenic in arsenate-treated mice. Toxicol Appl Pharmacol, 249, 217-23
143. Hughes MF, Beck BD, Chen Y, et al. (2011). Arsenic exposure and toxicology: a historical perspective. Toxicol Sci, 123, 305-32
144. International Agency for Research on Cancer Working Group (IARC Working Group). (1999). Consensus report. IARC Sci Pub, 147, 1-32.International Agency for Research on Cancer. (2004)
145. Some drinkingwater disinfectants and contaminants, including arsenic. IARC Monogr Eval Carcinog Risks Hum, 84, 39-229
146. International Agency for Research on Cancer. (2012). Arsenic, metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum, 100, 41-93
147. Jackson BP, Taylor VF, Karagas MR, et al. (2012). Arsenic, organic foods, and brown rice syrup. Environ Health Perspect, 120, 623-6
148. Jacquez GM, Slotnick MJ, Meliker JR, et al. (2011). Accuracy of commercially available residential histories for epidemiologic studies. Am J Epidemiol, 173, 236-43
149. Jiang G, Gong Z, Li XF, et al. (2003). Interaction of trivalent arsenicals with metallothionein. Chem Res Toxicol, 16, 873-80
150. Jiang X, McDermott JR, Ajees AA, et al. (2010). Trivalent arsenicals and glucose use different translocation pathways in mammalian GLUT1. Metallomics, 2, 211-19
151. Jurek AM, Greenland S, Maldonado G. (2008). How far from nondifferential does exposure or disease misclassification have to be to bias measures of association away from the null? Int J Epidemiol, 37, 382-5
152. Karagas MR, Stukel TA, Morris JS, et al. (2001). Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am J Epidemiol, 153, 559-65
153. Karagas MR, Tosteson TD, Morris JS, et al. (2004). Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire. Cancer Causes Control, 15, 465-72
154. Kenyon EM, Hughes MF, Adair BM, et al. (2008a). Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water. Toxicol Appl Pharmacol, 232, 448-55
155. Kenyon EM, Klimecki WT, El-Masri H, et al. (2008b). How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review Toxicol Appl Pharmacol, 232, 359-68
156. Kishore U, Greenhough TJ, Waters P, et al. (2006). Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol, 43, 1293-315
157. Kitchin KT, Conolly R. (2010). Arsenic-induced carcinogenesis - Oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment Chem Res Toxicol, 23, 327-35
158. Kitchin KT, Wallace K. (2005). Arsenite binding to synthetic peptides based on the Zn finger region and the estrogen binding region of the human estrogen receptor-alpha. Toxicol Appl Pharmacol, 206, 66-72
159. Kitchin KT, Wallace K. (2008). The role of protein binding of trivalent arsenicals in arsenic carcinogenesis and toxicity. J Inorg Biochem, 102, 532-9
160. Klein CB, Leszczynska J, Hickey C, Rossman TG. (2007). Further evidence against a direct genotoxic mode of action for arsenic-induced cancer. Toxicol Appl Pharmacol, 222, 289-97
161. Kligerman AD, Doerr CL, Tennant AH, et al. (2003). Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ Mol Mutagen, 42, 192-205
162. Kligerman AD, Malik SI, Campbell JA. (2010). Cytogenetic insights into DNA damage and repair of lesions induced by a monomethylated trivalent arsenical. Mutat Res, 695, 2-8
163. Klimecki WT, Borchers AH, Egbert RE, et al. (1997). Effects of acute and chronic arsenic exposure of human-derived keratinocytes in an Iin Vvitro human skin equivalent system: a novel model of human arsenicism. Toxicol In Vitro, 11, 89-98
164. Knobeloch LM, Zierold KM, Anderson HA. (2006). Association of arsenic-contaminated drinking-water with prevalence of skin cancer in Wisconsins Fox River Valley. J Health Popul Nutr, 24, 206-13
165. Komissarova EV, Saha SK, Rossman TG. (2005). Dead or dying: the importance of time in cytotoxicity assays using arsenite as an example. Toxicol Appl Pharmacol, 202, 99-107
166. Kurttio P, Pukkala E, Kahelin H, et al. (1999). Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect, 107, 705-10
167. Lai Y, Zhao W, Chen C, et al. (2011). Role of DNA polymerase beta in the genotoxicity of arsenic. Environ Mol Mutagen, 52, 460-8
168. Lamm SH, Engel A, Kruse MB, et al. (2004). Arsenic in drinking water and bladder cancer mortality in the United States: an analysis based on 133 U.S. counties and 30 years of observation. J Occup Environ Med, 46, 298-306
169. Lamm SH, Engel A, Penn CA, et al. (2006). Arsenic cancer risk confounder in southwest Taiwan data set. Environ Health Perspect, 114, 1077-82
170. Lamm SH, Luo ZD, Bo FB, et al. (2007). An epidemiological study of arsenic-related skin disorders and skin cancer and the consumption of arsenic-contaminated well waters in Huhhot, Inner Mongolia, China. Hum Ecol Risk Assess, 13, 713-46
171. Lamm SH, Robbins S, Zhou C, et al. (2013). Bladder/lung cancer mortality in Blackfoot-disease (BFD)-endemic area villages with low (5150 ug/L) well water arsenic levels - An exploration of the dose-response Poisson analysis Regul Toxicol Pharmacol, 65, 147-56
172. Larson JL, Somji S, Zhou XD, et al. (2010a). Beclin-1 expression in normal bladder and in Cd2 and As3 exposed and transformed human urothelial cells (UROtsa). Toxicol Lett, 195, 15-22
173. Larson J, Yasmin T, Sens DA, et al. (2010b). SPARC gene expression is repressed in human urothelial cells (UROtsa) exposed to or malignantly transformed by cadmium or arsenite. Toxicol Lett, 199, 166-72
174. Le XC, Ma M, Lai W-M. (1999). Exposure to arsenosugars from seafood ingestion and speciation of urinary arsenic metabolites. In: Chappell WR, Abernathy CO, Calderon RL, eds. Arsenic Exposure and Health Effects. Oxford: Elsevier Science Ltd, 69-98
175. Le XC, Lu X, Ma M, et al. (2000). Speciation of key arsenic metabolic intermediates in human urine. Anal Chem, 72, 5172-7
176. Le XC, Lu X, Li X-F. (2004). Arsenic speciation. Anal Chem, 76, 26A-33A
177. Leonardi G, Vahter M, Clemens F, et al. (2012). Inorganic arsenic and basal cell carcinoma in areas of Hungary, Romania, and Slovakia: a case-control study. Environ Health Perspect, 120, 721-6
178. Lewis DR, Southwick JW, Ouellet-Hellstrom R, et al. (1999). Drinking
179. Li YM, Broome JD. (1999). Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res, 59, 776-80
180. Liao WT, Lan CC, Lee CH, Yu HS. (2011). Concentration-dependent cellular responses of arsenic in keratinocytes. Kaohsiung J Med Sci, 27, 390-5
181. Lindberg AL, Rahman M, Persson LA, Vahter M. (2008). The risk of arsenic induced skin lesions in Bangladeshi men and women is affected by arsenic metabolism and the age at first exposure. Toxicol Appl Pharmacol, 230, 9-16
182. Lindberg AL, Sohel N, Rahman M, et al. (2010). Impact of smoking and chewing tobacco on arsenic-induced skin lesions. Environ Health Perspect, 118, 533-8
183. Liu J, Liang SX, Lu YF, et al. (2011). Realgar and realgar-containing Liu-Shen-Wan are less acutely toxic than arsenite and arsenate. J Ethnopharmacol, 134, 26-31
184. Lu X, Arnold LL, Cohen SM, et al. (2003). Speciation of dimethylarsinous acid and trimethylarsine oxide in urine from rats fed with dimethylarsinic acid and dimercaptopropane sulfonate. Anal Chem, 75, 6463-8
185. Lu J, Chew EH, Holmgren A. (2007a). Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci., 104, 12288-93
186. Lu M, Wang H, Li XF, et al. (2007b). Binding of dimethylarsinous acid to cys-13a of rat hemoglobin is responsible for retention of arsenic in rat blood. Chem Res Toxicol, 20, 27-37
187. Lu YF, Wu Q, Yan JW, et al. (2011). Realgar, cinnabar, and An-Gong-Niu-Huang Wan are much less chronically nephrotoxic than common arsenicals and mercurials. Exp Biol Med (Maywood), 236, 233-9
188. Mandal BK, Ogra Y, Suzuki KT. (2001). Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenicaffected areas of West Bengal, India. Chem Res Toxicol, 14, 371-8
189. Mandal BK, Ogra Y, Anzai K, Suzuki KT. (2004). Speciation of arsenic in biological samples. Toxicol Appl Pharmacol, 198, 307-18
190. Marafante E, Vahter M, Norin H, et al. (1987). Biotransformation of dimethylarsinic acid in mouse, hamster and man. J Appl Toxicol, 7, 111-17
191. Marshall G, Ferreccio C, Yuan Y, et al. (2007). Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst, 99, 920-8
192. Mart?nez V, Creus A, Venegas W, et al. (2005) Micronuclei assessment in buccal cells of people environmentally exposed to arsenic in northern Chile. Toxicol Lett, 155, 319-27
193. Masci O, Bongarzone R. (1995). General Toxicity. In: Castellino N, Castillino P, Sannolo N eds. Inorganic Lead Exposure. Metabolsm and Intoxication. Boca Raton: CRC Press, Inc, 211-13
194. Mass MJ, Tennant A, Roop BC, et al. (2001). Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol, 14, 355-61
195. Mazumder DN. (2007). Arsenic and non-malignant lung disease. J Environ Sci Health A Tox Hazard Subst Environ Eng, 42, 1859-67
196. Mazumder DN, Haque R, Ghosh N, et al. (2000). Arsenic in drinking water and the prevalence of respiratory effects in West Bengal, India. Int J Epidemiol, 29, 1047-52
197. Medeiros M, Zheng X, Novak P, et al. (2012). Global gene expression changes in human urothelial cells exposed to low-level monomethylarsonous acid. Toxicology, 291, 102-12
198. Meek ME, Bucher JR, Cohen SM, et al. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol, 33, 591-653
199. Meliker JR, Wahl RL, Cameron LL, Nriagu JO. (2007). Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ. Health 2007, doi:10.1186/1476-069X-6-4
200. Meliker JR, Goovaerts P, Jacquez GM, Nriagu, JO. (2010a). Incorporating individual-level distributions of exposure error in epidemiologic analyses: an example using arsenic in drinking water and bladder cancer. Ann Epidemiol, 20, 750-8
201. Meliker JR, Slotnick MJ, Avruskin GA, et al. (2010b). Lifetime exposure to arsenic in drinking water and bladder cancer: a population-based case-control study in Michigan, USA. Cancer Causes Control, 21, 745-57
202. Melkonian S, Argos M, Pierce BL, et al. (2011). A prospective study of the synergistic effects of arsenic exposure and smoking, sun exposure, fertilizer use, and pesticide use on risk of premalignant skin lesions in Bangladeshi men. Am J Epidemiol, 173, 183-91
203. Michaud DS, Wright ME, Cantor KP, et al. (2004). Arsenic concentrations in prediagnostic toenails and the risk of bladder cancer in a cohort study of male smokers. Am J Epidemiol, 160, 853-9
204. Milton AH, Rahman M. (2002). Respiratory effects and arsenic contaminated well water in Bangladesh. Int J Environ Health Res., 12, 175-9
205. Mink PJ, Alexander DD, Barraj LM, et al. (2008). Low-level arsenic exposure in drinking water and bladder cancer: a review and metaanalysis. Regul Toxicol Pharmacol, 52, 299-310
206. Molin M, Ydersbond TA, Ulven SM, et al. (2012). Major and minor arsenic compounds accounting for the total urinary excretion of arsenic following intake of blue mussels (Mytilus edulis): a controlled human study. Food Chem Toxicol, 50, 2462-72
207. Moolgavkar, SH, Knudson Jr AG. (1981). Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst, 66, 1037-52
208. Moore LE, Smith AH, Hopenhayn-Rich C, et al. (1997). Micronuclei in exfoliated bladder cells among individuals chronically exposed to arsenic in drinking water. Cancer Epidemiol Biomarkers Prev., 6, 31-6
209. Moore LE, Smith AH, Eng C, et al. (2002). Arsenic-related chromosomal alterations in bladder cancer. J Natl Cancer Inst, 94, 1688-96
210. Moore LE, Smith AH, Eng C, et al. (2003). P53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis, 24, 1785-91
211. Mostafa MG, McDonald JC, Cherry NM. (2008). Lung cancer and exposure to arsenic in rural Bangladesh. Occup Environ Med, 65, 765-8
212. Mudipalli A, Owen RD, Preston RJ. (2005). The effect of arsenicals on ultraviolet-radiation-induced growth arrest and related signaling events in human keratinocytes. Int J Oncol, 27, 769-78
213. Mure K, Uddin AN, Lopez LC, et al. (2003). Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations. Environ Mol Mutagen, 41, 322-31
214. Naranmandura H, Ibata K, Suzuki KT. (2007). Toxicity of dimethylmonothioarsinic acid toward human epidermoid carcinoma A431 cells. Chem Res Toxicol, 20, 1120-5
215. Naranmandura H, Suzuki N, Suzuki KT. (2008). Reaction mechanism underlying the in vitro transformation of thioarsenicals. Toxicol Appl Pharmacol, 231, 328-35
216. Naranmandura H, Carew MW, Xu S, et al. (2011). Comparative toxicity of arsenic metabolites in human bladder cancer EJ-1 cells. Chem Res Toxicol, 24, 1586-96
217. Nascimento MG, Suzuki S, Wei M, et al. (2008). Cytotoxicity of combinations of arsenicals on rat urinary bladder urothelial cells in vitro. Toxicology, 249, 69-74
218. National Research Council (NRC). (1999). Arsenic in Drinking Water. Subcommittee on Arsenic in Drinking Water. Washington, DC: National Academy Press, 310
219. National Research Council (NRC). (2001). Arsenic in Drinking Water: 2001 Update. Subcommittee on Arsenic in Drinking Water. Washington, DC: National Academy Press, 189
220. National Toxicology Program (NTP). (2000). NTP toxicology and carcinogenesis studies of gallium arsenide (CAS No. 1303-00-0) in F344/N rats and B6C3F1 mice (inhalation studies) Natl Toxicol Program Tech Rep Ser, 492, 1-306
221. National Toxicology Program (NTP). (2011). Malarkey DE, Bucher JR. Summary Report of the National Toxicology Program and Environmental Protection Agency-Sponsored Review of Pathology Materials from Selected Ramazzini Institute Rodent Cancer Bioassays. Available at: http://ntp.niehs.nih.gov/NTP/About-NTP/ Partnerships/International/SummaryPWG-Report-RI-Bioassays.pdf. Accessed on [last accessed 11 February 2013
222. Navas-Acien A, Francesconi KA, Silbergeld EK, Guallar E. (2011). Seafood intake and urine concentrations of total arsenic, dimethylarsinate and arsenobetaine in the US population. Environ Res, 111, 110-18
223. Nelson GM, Ahlborn GJ, Allen JW, et al. (2009). Transcriptional changes associated with reduced spontaneous liver tumor incidence in mice chronically exposed to high dose arsenic. Toxicology, 266, 6-15
224. Nemeti B, Anderson ME, Gregus Z. (2012). Glutathione synthetase promotes the reduction of arsenate via arsenolysis of glutathione. Biochimie, 94, 1327-33
225. Nersesyan A, Kundi M, Atefie K, et al. (2006). Effect of staining procedures on the results of micronucleus assays with exfoliated oral mucosa cells. Cancer Epidemiol Biomarkers Prev, 15, 1835-40
226. Nesnow S, Roop BC, Lambert G, et al. (2002). DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol, 15, 1627-34
227. Ngu TT, Stillman MJ. (2006). Arsenic binding to human metallothionein. J Am Chem Soc, 128, 12473-83
228. Nicolis I, Curis E, Deschamps P, Benazeth, S. (2009). Arsenite medicinal use, metabolism, pharmacokinetics and monitoring in human hair. Biochimie, 91, 1260-7
229. Nikitin AY, Alcaraz A, Anver MR, et al. (2004). Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res, 64, 2307-16 Erratum in Cancer Res, 64, 3725
230. Pan X, Reissman S, Douglas NR, et al. (2010). Trivalent arsenic inhibits the functions of chaperonin complex. Genetics, 186, 725-34
231. Parvez F, Chen Y, Brandt-Rauf PW, et al. (2008). Nonmalignant respiratory effects of chronic arsenic exposure from drinking water among never-smokers in Bangladesh. Environ Health Perspect, 116, 190-5
232. Parvez F, Chen Y, Brandt-Rauf PW, et al. (2010). A prospective study of respiratory symptoms associated with chronic arsenic exposure in Bangladesh: findings from the Health Effects of Arsenic Longitudinal Study (HEALS). Thorax, 65, 528-33
233. Petito-Boyce C, Lewis AS, Sax SN, et al. (2008). Probabilistic analysis of human health risks associated with background concentrations of inorganic arsenic: use of a margin of exposure approach. Hum Ecol Risk Assess, 14, 1159-201
234. Pinyayev TS, Kohan MJ, Herbin-Davis K, et al. (2011). Preabsorptive metabolism of sodium arsenate by anaerobic microbiota of mouse cecum forms a variety of methylated and thiolated arsenicals. Chem Res Toxicol, 24, 475-7
235. Plopper CG, Hill LH, Mariassy AT. (1980). Ultrastructure of the nonciliated bronchiolar epithelial (Clara) cell of mammalian lung. III. A study of man with comparison of 15 mammalian species. Exp Lung Res, 1, 171-80
236. Pou SA, Osella AR, Diaz Mdel P. (2011). Bladder cancer mortality trends and patterns in Cordoba, Argentina (1986-2006) Cancer Causes Control, 22, 407-15
237. Qin LJ, Liu W, Li YN, et al. (2012) Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure. Toxicol Sci, 127, 120-9
238. Raml R, Rumpler A, Goessler W, et al. (2007). Thio-dimethylarsinate is a common metabolite in urine samples from arsenic-exposed women in Bangladesh. Toxicol Appl Pharmacol, 222, 374-80
239. Raml R, Raber G, Rumpler A, et al. (2009). Individual variability in the human metabolism of an arsenic-containing carbohydrate, 20,30-dihydroxypropyl 5-deoxy-5-dimethylarsinoyl-beta-D-riboside, a naturally occurring arsenical in seafood. Chem Res Toxicol, 22, 1534-40
240. Reay PF, Asher CJ. (1977). Preparation and purification of 74As-labeled arsenate and arsenite for use in biological experiments. Anal Biochem, 78, 557-60
241. Rehman K, Naranmandura H. (2012). Arsenic metabolism and thioarsenicals. Metallomics, 24, 881-92
242. Rehman K, Chen Z, Wang WW, et al. (2012). Mechanisms underlying the inhibitory effects of arsenic compounds on protein tyrosine phosphatase (PTP). Toxicol Pathol Pharmacol, 263, 273-80
243. Reichard JF, Schnekenburger M, Puga A. (2007). Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem Biophys Res Commun, 352, 188-92
244. Ren X, Aleshin M, Jo WJ, et al. (2011). Involvement of N-6 adeninespecific DNA methyltransferase 1 (N6AMT1) in arsenic biomethylation and its role in arsenic-induced toxicity. Environ Health Perspect, 119, 771-7
245. Rossman TG, Klein CB. (2011). Genetic and epigenetic effects of environmental arsenicals. Metallomics, 3, 1135-41
246. Rossman TG, Uddin AN, Burns FJ. (2004). Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicol Appl Pharmacol, 198, 394-404
247. Salim EI, Wanibuchi H, Morimura K, et al. (2003). Carcinogenicity of dimethylarsinic acid in p53 heterozygous knockout and wild-type C57BL/6J mice. Carcinogenesis, 24, 335-42
248. Sampayo-Reyes A, Hernandez A, El-Yamani N, et al. (2010). Arsenic induces DNA damage in environmentally exposed Mexican children and adults. Influence of GSTO1 and AS3MT polymorphisms. Toxicol Sci, 117, 63-71
249. Schmidt, AC, Mickein, K. (2011). Optimization of peptide and protein separation with a monolithic reversed-phase column and application to arsenic-binding studies. J. Chromatogr. A., 1218, 280-5
250. Schmidt A C, Mickein K. (2012). Qualitative and quantitative characterization of the arsenic-binding behaviour of sulfur-containing peptides and proteins by the coupling of reversed phase liquid chromatography to electrospray ionization mass spectrometry. J Mass Spectrom, 47, 949-61
251. Schoen A, Beck B, Sharma R, Dube E. (2004). Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicol Appl Pharmacol, 198, 253-67
252. Schuhmacher-Wolz U, Dieter HH, Klein D, Schneider K. (2009). Oral exposure to inorganic arsenic: evaluation of its carcinogenic and noncarcinogenic effects. Crit Rev Toxicol, 39, 271-98
253. Schwartz RA. (1996). Premalignant keratinocytic neoplasms. J Am Acad Dermatol, 35, 223-42
254. Seed J, Carney EW, Corley RA, et al. (2005). Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol, 35, 664-72
255. Sen B, Wolf DC, Turpaz Y, et al. (2007). Identification of interspecies concordance of mechanisms of arsenic-induced bladder cancer. Toxicol In Vitro, 21, 1513-29
256. Sens DA, Park S, Gurel V, et al. (2004). Inorganic cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. Toxicol Sci, 79, 56-63
257. Seow WJ, Pan W-C, Kile ML, et al. (2012). Arsenic reduction in drinking water and improvement in skin lesions: a follow-up study in Bangladesh. Environ Health Perspect, 120, 1733-8
258. Shen S, Lee J, Cullen WR, et al. (2009). Arsenite and its mono- and dimethylated trivalent metabolites enhance the formation of benzo[a]pyrene diol epoxide-DNA adducts in Xerderma pimentosum complementation group A cells. Chem Res Toxicol, 22, 382-90
259. Simeonova PP, Wang S, Toriuma W, et al. (2000). Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation. Cancer Res, 60, 3445-53
260. Slaga TJ. (1983a). Cellular and molecular mechanisms of tumour promotion. Cancer Surveys, 2, 595-612
261. Slaga TJ. (1983b). Overview of tumor promotion in animals. Environ. Health Perspect, 50, 3-14
262. Smeester L, Rager JE, Bailey KA, et al. (2011). Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol, 24, 165-7
263. Smith AH, Ercumen AY, Yuan YA, Steinmaus CM. (2009). Increased lung cancer risks are similar whether arsenic is ingested or inhaled. J Expo Sci Environ Epidemiol, 19, 343-8
264. Smith AH, Hopenhayn-Rich C, Warner M, et al. (1993). Rationale for selecting exfoliated bladder cell micronuclei as potential biomarkers for arsenic genotoxicity. J Toxicol Environ Health, 40, 223-34
265. Smith AH, Goycolea M, Haque R, Biggs ML. (1998). Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol, 147, 660-9
266. Smith AH, Marshall G, Liaw J, et al. (2012). Mortality in young adults following in utero and childhood exposure to arsenic in drinking water. Environ Health Perspect, 120, 1527-31
267. Smith AH, Marshall G, Yuan Y, et al. (2006). Increased mortality from lung cancer and bronchiectasis in young adults following exposure to arsenic in utero and early childhood. Environ Health Perspect, 114, 1293-6
268. Soffritti M, Belpoggi F, Degli Esposti D, Lambertini L. (2006). Results of a long-term carcinogenicity bioassay on Sprague-Dawley rats exposed to sodiium arsenite administered in drinking water. Ann NfY Acad Sci, 1076, 578-91
269. Sonich-Mullin C, Fielder R, Wiltse J, et al. (2001). International Programme on Chemical Safety. IPCS conceptual framework for evaluating a MOA for chemical carcinogenesis. Regul Toxicol Pharmaco., 34, 146-52
270. States JC, Barchowsky A, Cartwright IL, et al. (2011). Arsenic toxicology: translating between experimental models and human pathology. Environ Health Perspect, 119, 1356-63
271. Steinmaus CM, Ferreccio C, Acevedo Romo J et al. (2013). Drinking water arsenic in northern Chile: high cancer risks 40 years after exposure cessation. Cancer Epidemiol Biomarkers Prev 2013, doi:10.1158/1055-9965.EPI-12-1190
272. Steinmaus C, Yuan Y, Bates MN, Smith AH. (2003). Case-control study of bladder cancer and drinking water arsenic in the western United States. Am J Epidemiol, 158, 1193-2001
273. Sumi D, Fukushima K, Miyataka H, Himeno S. (2011). Alternative splicing variants of human arsenic (3 oxidation state) methyltransferase. Biochem Biophys Res Commun, 415, 48-53
274. Sun Y, Tokar EJ, Waalkes MP. (2012). Overabundance of putative cancer stem cells in human skin keratinocyte cells malignantly transformed by arsenic. Toxicol Sci, 125, 20-9
275. Suzuki S, Arnold LL, Muirhead D, et al. (2008a). Inorganic arsenic- induced intramitochondrial granules in mouse urothelium Toxicol Pathol, 36, 999-1005
276. Suzuki S, Arnold LL, Ohnishi T, Cohen SM. (2008b). Effects of inorganic arsenic on the rat and mouse urinary bladder. Toxicol Sci, 106, 350-63
277. Suzuki S, Arnold LL, Pennington K, et al. (2009). Effects of co-administration of dietary sodium arsenite and a NADPH oxidase inhibitor on the rat bladder epithelium. Toxicology, 261, 241-6
278. Suzuki S, Arnold LL, Pennington KL, et al. (2010). The dose effects of dietary administration of sodium arsenite on the urinary concentrations of arsenicals, including thio-metabolites, and on the urinary bladder epithelium. Toxicol Appl Pharm, 244, 99-105
279. Tajima H, Yoshida T, Ohnuma A, et al. (2010). Pulmonary injury and antioxidant response in mice exposed to arsenate and hexavalent chromium and their combination. Toxicology, 267, 118-24
280. Taleshi MS, Edmonds JS, Goessler W, et al. (2010). Arsenic-containing lipids are natural constituents of sashimi tuna. Environ Sci Technol, 44, 1478-83
281. Thomas DJ. (2007). Molecular processes in cellular arsenic metabolism. Toxicol Appl Pharmacol, 222, 365-73
282. Thomas DJ. (2009). Unraveling arsenic-glutathione connections Toxicol Sci, 107, 309-11
283. Thomas DJ. (2010). Arsenolysis and thiol-dependent arsenate reduction. Toxicol Sci, 117, 249-52
284. Tian J, Zhao H, Nolley R, et al. (2012) Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Clin Cancer Res, 18, 3366-76
285. Tokar EJ, Diwan BA, Waalkes MP. (2010a). Arsenic exposure in utero and nonepidermal proliferative response in adulthood in Tg.AC mice. Int J Toxicol, 29, 291-6
286. Tokar EJ, Benbrahim-Tallaa L, Ward JM, et al. (2010b). Cancer in experimental animals exposed to arsenic and arsenic compounds. Crit Rev Toxicol, 40, 912-27
287. Tokar EJ, Diwan BA, Ward JM, et al. (2011). Carcinogenic effects of whole-life exposure to inorganic arsenic in CD1 mice. Toxicol Sci, 119, 73-83
288. Tokar EJ, Diwan BA, Waalkes MP. (2012). Tumors and proliferative lesions in adult offspring after maternal exposure to methylarsonous acid during gestation in CD1 mice. Arch Toxicol, 86, 975-82
289. Tondel M, Rahman M, Magnuson A, et al. (1999). The relationship of arsenic levels in drinking water and the prevalence rate of skin lesions in Bangladesh. Environ. Health Perspect., 107, 727-9
290. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC eds. (2004). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon France: IARC Press, 9-122
291. Trouba KJ, Germolec DR. (2004). Micromolar concentrations of sodium arsenite induce cyclooxygenase-2 expression and stimulate p42/44 mitogen-activated protein kinase phosphorylation in normal human epidermal keratinocytes. Toxicol Sci, 79, 248-57
292. Trouba KJ, Glanzer JG, Vorce RL. (1999). Wild-type and Rastransformed fibroblasts display differential mitogenic responses to transient sodium arsenite exposure. Toxicol Sci, 50, 72-81
293. Tsai SM, Wang TN, Ko YC. (1999). Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch Environ Health, 54, 186-93
294. Tseng W-P. (1977). Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ. Health Perspect, 19, 109-19
295. Tseng WP, Chu HM, How SW. (1968). Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst, 40, 453-63
296. Tsuji JS, Alexander DD, Perez V. (2013). Low-level arsenic in drinking water and bladder cancer risk: meta-analysis update and risk assessment implications. Poster presentation, 52nd Annual Society of Toxicology Meeting, March, San Antonio, TX.
297. Tucker SP, Lamm SH, Li FX et al. (2001). Relationship between consumption of arsenic-contaminated well water and skin disorders in Huhhot, Inner Mongolia. Available at: http://phys4.harvard.edu/-wilson/arsenic/references/ imcap/IMCAP-report.html. July 5, 33. Accessed 18 April 2013
298. US EPA. (2007). Letter to S. Johnson (US EPA) re: advisory on EPAs assessments of carcinogenic effects of organic and inorganic arsenic: a report of the US EPA Science Advisory Board. EPA-SAB-07-008, June 28, 88
299. US EPA. (2010). Toxicological review of inorganic arsenic in support of summary information on the Integrated Risk Information System (IRIS), Notice of public comment period. Fed Reg, 75, 7477-9
300. Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, et al. (2005). Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect, 113, 250-4
301. Valenzuela OL, Drobna Z, Hernandez-Castellanos E, et al. (2009). Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol Appl Pharmacol, 239, 200-7
302. Vega L, Styblo M, Patterson R, et al. (2001). Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol, 172, 225-32
303. Villa-Bellosta R, Sorribas V. (2010). Arsenate transport by sodium/phosphate cotransporter type IIb. Toxicol Appl Pharmacol, 247, 36-40
304. von Ehrenstein OS, Mazumder DN, Yuan Y, et al. (2005). Decrements in lung function related to arsenic in drinking water in West Bengal, India. Am J Epidemiol, 162, 533-41
305. Waalkes MP, Ward JM, Liu J, Diwan BA. (2003). Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol Appl Pharmacol, 186, 7-17
306. Waalkes MP, Ward JM, Diwan BA. (2004). Induction of tumors of the liver, lung, ovary, and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers. Carcinogenesis, 25, 133-1341
307. Waalkes MP, Liu J, Ward JM, Diwan BA. (2006). Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen. Toxicol Appl Pharmacol, 215, 295-305
308. Waalkes MP, Liu J, Germolec DR, et al. (2008). Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics. Cancer Res, 68, 8278-85
309. Wang A, Kligerman AD, Holladay SD, et al. (2009). Arsenate and dimethylarsinic acid in drinking water did not affect DNA damage repair in urinary bladder transitional cells or micronuclei in bone marrow. Environ Mol Mutagen, 50, 760-70
310. Wang YH, Yeh SD, Wu MM et al. (2012). Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular growth factor on upper urinary tract urothelial carcinoma and bladder cancer. J Hazard Mater Accession Number: 23009795
311. Wanibuchi H, Salim EI, Kinoshita A, et al. (2004). Understanding arsenic carcinogenicity by the use of animal models. Toxicol Appl Pharmacol, 198, 366-76
312. Warner ML, Moore LE, Smith MT, et al. (1994). Increased micronuclei in exfoliated bladder cells of individuals who chronically ingest arsenic-contaminated water in Nevada. Cancer Epidemiol Biomarkers Prev, 3, 583-90
313. Waters SB, Devesa V, Del Razo LM, et al. (2004). Endogenous reductants support the catalytic function of recombinant rat cyt19, an arsenic methyltransferase. Chem Res Toxicol, 17, 404-9
314. Wedel WR, Muirhead DE, Arnold LL et al. (2013). Urothelial cell intracytoplasmic inclusions after treatment of promyelocytic leukemia with arsenic trioxide. Toxicol Sci doi: 10.1093/toxsci/kft120
315. Wei M, Wanibuchi H, Yamamoto S, et al. (1999). Urinary bladder carcinogenicity of dimethylarsinic acid in male F344 rats. Carcinogenesis, 20, 1873-6
316. Wei M, Wanibuchi H, Morimura K, et al. (2002). Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis, 23, 1387-97
317. Wei C, LiW, Zhang C, et al. (2003). Safety evaluation of organoarsenical species in edible Porphyra from the China Sea. J Agric Food Chem, 51, 5176-82
318. Wei M, Arnold LL, Cano M, Cohen SM. (2005). Effects of co-administration of antioxidants and arsenicals on the rat urinary bladder epithelium. Toxicol Sci, 83, 237-45
319. Wnek SM, Jensen TJ, Severson PL, et al. (2010). Monomethylarsonous acid produces irreversible events resulting in malignant transformation of a human bladder cell line following 12 weeks of low-level exposure. Toxicol Sci, 116, 44-57
320. Wu XR. (2005). Urothelial tumorigenesis, a tale of divergent pathways. Nat Rev Cancer, 5, 713-25
321. Wu MM, Kuo TL, Hwang YH, Chen CJ. (1989). Dose-response relationship between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol, 130, 1123-32
322. Wu XR, Kong XP, Pellicer A, et al. (2009). Uroplakins in urothelial biology, function, and disease. Kidney Int, 75, 1153-65
323. Xu Y, Wang Y, Zheng Q, et al. (2008). Clinical manifestations and arsenic methylation after a rare subacute arsenic poisoning accident. Toxicol Sci, 103, 278-84
324. Xu Y, Tokar EJ, Sun Y, Waalkes MP. (2012). Arsenic-transformed malignant prostate epithelia can convert noncontiguous normal stem cells into an oncogenic phenotype. Environ Health Perspect, 120, 865-71
325. Xue J, Zartarian V, Wang S-W, et al. (2010). Probabilistic modeling of dietary arsenic exposure and dose and evaluation with 2003-2004 NHANES data Environ Health Perspect, 118, 345-50
326. Yager JW, Gentry PR, Thomas RS, et al. (2013). Evaluation of gene express changes in human primary uroepithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites. Environ Mol Mutagen, 54, 82-98
327. Yan H, Wang N, Weinfeld M, et al. (2009) Identification of arsenicbinding proteins in human cells by affinity chromatography and mass spectrometry. Anal Chem, 81, 4144-52
328. Yang CY, Chiu HF, Chang CC, et al. (2005). Bladder cancer mortality reduction after installation of a tap-water supply system in an arsenious-endemic area in southwestern Taiwan. Environ Res, 98, 127-32
329. Yang, L, Peterson PJ, Williams WP, et al. (2002). The relationship between exposure to arsenic concentrations in drinking water and the development of skin lesions in farmers from Inner Mongolia, China. Environ Geochem Health, 24, 293-303
330. Ying S, Myers K, Bottomley S, et al. (2009). BRCA2-dependent homologous recombination is required for repair of Arsenite-induced replication lesions in mammalian cells. Nucleic Acids Res, 37, 5105-13
331. Yokohira M, Arnold LL, Pennington KL, et al. (2010). Severe systemic toxicity and urinary bladder cytotoxicity and regenerative hyperplasia induced by arsenite in arsenic (3 oxidation state) methyltransferase knockout mice. A preliminary report. Toxicol Appl Pharm, 246, 1-7
332. Yokohira M, Arnold LL, Pennington KL, et al. (2011). Effect of sodium arsenite dose administered in the drinking water on the urinary bladder epithelium of female arsenic (3 oxidation state) methyltransferase knockout mice. Toxicol Sci, 121, 257-66
333. Yu HS, Liao WT, Chai CY. (2006). Arsenic carcinogenesis in the skin. J Biomed Sci, 13, 657-66
334. Zeiger E. (2001). Mutagens that are not carcinogens: faulty theory or faulty tests? Mutat. Res, 492:29-38
335. Erratum in: Mutat Res 498, 219. Zeiger E. (2004). History and rationale of genetic toxicity testing: an impersonal, and sometimes personal, view. Environ Mol Mutagen, 44, 363-71
336. Zhang XW, Yan XJ, Zhou ZR, et al. (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 238, 240-3
337. Zhao L, Gao Y, Yang Y, et al. (2010). Serum Proteomic profiling analysis of chronic arsenic exposure by using SELDI-TOF-MS technology. Toxicol Lett, 195, 155-60
338. Zhou X, Sun X, Cooper KL, et al. (2011). Arsenite interacts selectively with zinc finger proteins containing C3H1 or C4 motifs. J Biol Chem, 286, 22855-63.